Genodermatoses with Systemic Significance — Skin as the Window to the Genome

The answer first

Genodermatoses are inherited skin disorders in which a visible cutaneous sign is the clue to a multisystem disease. The physician's job is to recognise the pattern, apply the consensus diagnostic criteria, and then orchestrate the surveillance — ophthalmology, cardiology, neurology, gastroenterology, oncology — that these syndromes demand. ^[1]

A consultant-grade answer rests on four pillars: ^[1]

1. Apply the published diagnostic criteria before accepting the label. NF1 uses the revised Legius 2021 consensus, TSC uses the 2021 International criteria, HHT uses the Curaçao criteria, and Sturge-Weber is clinical plus the somatic GNAQ mosaic finding — each set of criteria defines who needs molecular testing and who needs imaging. ^{[1] [2] [3] [4]}
2. Surveil the dangerous systemic complications in advance, not after they declare. NF1 requires periodic blood pressure, ophthalmology, growth and developmental review through childhood, with MRI when a plexiform neurofibroma or optic pathway glioma is suspected; TSC mandates brain MRI, renal ultrasound and echocardiography; HHT mandates pulmonary and cerebral AVM screening; pseudoxanthoma elasticum mandates retinal and cardiovascular surveillance. ^{[9] [10] [6] [11]}
3. Recognise the targeted therapies with randomised evidence. Selumetinib (an oral MEK1/2 inhibitor) achieved a significant objective response versus placebo in adults with symptomatic, inoperable plexiform neurofibromas (KOMET phase 3: 20% versus 5%), and everolimus (mTOR inhibitor) for subependymal giant-cell astrocytoma and renal angiomyolipoma in TSC. ^{[8] [2]}
4. Counsel families with accurate inheritance risk. NF1, TSC, HHT and Darier disease are autosomal dominant with variable expressivity; pseudoxanthoma elasticum is autosomal recessive; Sturge-Weber is sporadic somatic GNAQ mosaicism; X-linked ichthyosis is X-linked recessive — carrier mothers have a 50% risk to each son, and larger STS deletions can involve contiguous genes. ^{[1] [6] [7]}

DWE high-yield: "The skin is the map." Six café-au-lait macules plus axillary freckling is NF1; ash-leaf hypomelanosis plus seizures is TSC; a V1 port-wine stain plus hemiparesis is Sturge-Weber; recurrent epistaxis with mucocutaneous telangiectases is HHT — each cutaneous pattern unlocks a defined surveillance programme that the physician must initiate. ^{[1] [2] [3] [4]}

References12ShowHide

1. [1]Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med, 2021.PMID 34012067
2. [2]Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol, 2021.PMID 34399110
3. [3]McDonald J, Bayrak-Toydemir P, DeMille D, et al. Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2). Genet Med, 2020.PMID 32300199
4. [4]Ramirez EL, Jülich K Sturge-Weber syndrome: an overview of history, genetics, clinical manifestations, and management. Semin Pediatr Neurol, 2024.PMID 39389653
5. [5]Ettinger M, Kimeswenger S, Deli I, et al. Darier disease: Current insights and challenges in pathogenesis and management. J Eur Acad Dermatol Venereol, 2025.PMID 39606894
6. [6]Germain DP Pseudoxanthoma elasticum. Orphanet J Rare Dis, 2017.PMID 28486967
7. [7]Zhou B, Liang C, Li P, et al. Revisiting X-linked congenital ichthyosis. Int J Dermatol, 2025.PMID 39086014
8. [8]Chen AP, Coyne GO, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet, 2025.PMID 40473450
9. [9]Kerashvili N, Gutmann DH The management of neurofibromatosis type 1 (NF1) in children and adolescents. Expert Rev Neurother, 2024.PMID 38406862
10. [10]Hammill AM, Wusik K, Kasthuri RS Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management. Hematology Am Soc Hematol Educ Program, 2021.PMID 34889398
11. [11]Miller DT, Freedenberg D, Schorry E, et al. Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics, 2019.PMID 31010905
12. [12]Wataya-Kaneda M Tuberous Sclerosis Complex. Keio J Med, 2025.PMID 37532517